Nippon Care Supply Co Ltd

Nippon Care Supply maintains a conservative capital structure with a debt-to-equity ratio of 0.06, significantly below the industry median of 0.35, indicating minimal leverage risk. The company's liquidity position is characterized by a current ratio of 0.83, which is below the industry median of 1.2, suggesting potential short-term liquidity constraints. Free cash flow of 7.72 billion JPY supports operational flexibility, though cash and equivalents of 692.64 million JPY are insufficient to cover total debt of 1.06 billion JPY, resulting in a net cash negative position. Profitability metrics show a return on equity (ROE) of 12.14% and a return on assets (ROA) of 8.14%, both exceeding the industry medians of 9.5% and 6.2%, respectively. This outperformance is driven by a gross margin of 36.6% (12.79 billion JPY gross profit on 34.93 billion JPY revenue), which is above the sector median of 32.1%. Operating income of 3.09 billion JPY reflects strong cost control, though net income of 2.26 billion JPY is constrained by interest and tax expenses. The company's revenue is concentrated in Japan, with no disclosed international operations. Segment data is not available in the latest filing, but the business is primarily focused on medical equipment and supply distribution. This concentration exposes the company to domestic healthcare policy shifts and currency fluctuations. Outlook for the current fiscal year indicates stable revenue growth, with a projected increase of 2.1% year-over-year. Capital expenditure of -667.85 million JPY suggests asset optimization rather than expansion. The next fiscal year is expected to see a 3.4% revenue increase, driven by demand for medical supplies in the aging Japanese population. Risk assessment highlights medium liquidity risk due to the current ratio below 1.0 and a net cash negative position. Dilution risk is low, with no near-term share issuance plans disclosed. The company's conservative leverage and strong profitability mitigate credit risk, though the liquidity profile warrants monitoring. Recent filings and transcripts show no material changes in business strategy or regulatory exposure. The company continues to focus on domestic healthcare infrastructure and supply chain efficiency.